NCT03955783 - Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions

Diffuse Large B-cell LymphomaAcute Myeloid LeukemiaNon-Hodgkin's Lymphoma

Interventions

DRUG

Venetoclax

Given by mouth

DRUG

Selinexor

Given by mouth

Trial Locations (4)

Roswell Park Cancer Center, Buffalo

Vanderbilt-Ingram Cancer Center, Nashville

University Hospitals of Cleveland, Cleveland

University of Texas Southwestern Medical Center, Dallas